@article{a38c5e1956f34089a4853d40e6cd1477,
title = "Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study",
abstract = "Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma.",
keywords = "Adult, Aged, Aged, 80 and over, Carcinoma, Hepatocellular, Disease-Free Survival, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions, Female, Gene Expression, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-met, Pyrrolidinones, Quinolines, Adult, Aged, Aged, 80 and over, Carcinoma, Hepatocellular, Disease-Free Survival, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions, Female, Gene Expression, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-met, Pyrrolidinones, Quinolines",
author = "Armando Santoro and Lorenza Rimassa and Ivan Borbath and Bruno Daniele and Stefania Salvagni and {Van Laethem}, {Jean Luc} and {Van Vlierberghe}, Hans and J{\"o}rg Trojan and Kolligs, {Frank T} and Alan Weiss and Steven Miles and Antonio Gasbarrini and Monica Lencioni and Luca Cicalese and Morris Sherman and Cesare Gridelli and Peter Buggisch and Guido Gerken and Schmid, {Roland M} and Corrado Boni and Nicola Personeni and Ziad Hassoun and Giovanni Abbadessa and Brian Schwartz and {Von Roemeling}, Reinhard and Lamar, {Maria E} and Yinpu Chen and Camillo Porta",
year = "2013",
doi = "10.1016/S1470-2045(12)70490-4",
language = "English",
volume = "14",
pages = "55--63",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
}